One of the most respected magazines in the country mentioned MBI in a report about scientific advances in the treatment of medulloblastoma.
With more than 50 years of history, Exame is a national reference in economic, scientific, and innovation journalism. Since 2020, it has been part of the BTG Pactual Group, consolidating itself as one of the most prestigious and far-reaching publications in Brazil.
The article highlights the beginning of the first clinical trials conducted by MBI, involving two patients treated through personalized immunotherapy: an innovative approach designed to strengthen the immune system to attack the tumor’s DNA.
It also presents the journey of Fernando Goldsztein, founder of the initiative, and the international collaboration led by Dr. Roger Packer, which now includes 16 laboratories in different countries working toward a shared goal: developing therapies that are more effective and less aggressive.
Our focus is clear: to turn devastating diagnoses into treatable conditions, bringing more hope and quality of life to thousands of children.
Each mention of MBI is more than recognition, it’s a sign that purpose-driven science is gaining the space it deserves in the public conversation.
It reinforces the trust of partners and donors, expands dialogue with society, and inspires the continuation of a global movement that believes collaboration saves lives.
Read the full article here and donate through this link
